The global elotuzumab market was valued at USD 1.27 billion in 2025. The market is projected to grow from USD 1.38 billion in 2026 to USD 2.69 billion by 2034, exhibiting a compound annual growth rate of 8.7% during the forecast period. Contrive Datum Insights presents this information in its report titled "Elotuzumab Market Size, Share & Industry Analysis, By Type (300mg Injection, 400mg Injection), Application (Hospital, Clinic, Drug Center, Other), Distribution channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies), Combination regimen (Elotuzumab + Lenalidomide + Dexamethasone, Elotuzumab + Pomalidomide + Dexamethasone, Other Combinations), Treatment line (Second-Line Therapy, Third-Line and Later, Other Treatment Lines), and Regional Forecast, 2026-2034".
Elotuzumab is a monoclonal antibody that targets the SLAMF7 protein on myeloma and natural killer cells, administered by intravenous infusion in combination with other anti-myeloma agents rather than as a standalone therapy. It is used to treat adult patients with relapsed or refractory multiple myeloma who have already received one or more prior lines of treatment. Purchasers are hospital and specialty oncology pharmacies that supply infusion centers, clinics and drug treatment centers where oncologists administer the combination regimen.
Rising multiple myeloma incidence and prevalence expanding the eligible relapsed or refractory patient pool
Rising multiple myeloma incidence and prevalence expanding the eligible relapsed or refractory patient pool is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 8.7% a year, the type lines exposed to it move fastest: 400mg Injection compounds at 9.36%, taking its share of revenue from 56.77% to 60% and its value from USD 0.721 billion to USD 1.614 billion.
Where the forecast could be beaten: the bull case assumes broader payer coverage and faster uptake of elotuzumab-based combination regimens across relapsed and refractory patient lines, with fewer delays in reimbursement approvals in expansion markets. The study puts that case at USD 3.013 billion in 2034, against USD 2.69 billion in the base.
The downside is specific. The bear case assumes accelerated share loss to newer anti-CD38 and BCMA-targeted alternatives in later treatment lines, alongside tighter payer scrutiny that slows combination-regimen adoption in price-sensitive markets, and 2034 revenue lands at USD 2.367 billion. 300mg Injection is the drag, 43.23% of the 2025 base compounding at 7.78% while the market runs at 8.7%.
One Type Line Holds Both Positions
Unusually, scale and growth sit in the same place. 400mg Injection holds 56.77% of 2025 revenue (USD 0.721 billion) and still compounds at 9.36%, reaching 60% of the market by 2034. That removes the usual trade-off between defending volume and chasing growth, and it raises what a challenger has to overcome in a market of USD 1.27 billion.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | 400mg Injection | 56.77% · USD 0.721 billion | — |
| Application | Hospital | 61.97% · USD 0.787 billion | Clinic 10.12% |
| Distribution channel | Hospital Pharmacies | 48.03% · USD 0.61 billion | Online Pharmacies 11.57% |
| Combination regimen | Elotuzumab + Lenalidomide + Dexamethasone | 64.02% · USD 0.813 billion | Elotuzumab + Pomalidomide + Dexamethasone 11.91% |
| Treatment line | Second-Line Therapy | 54.02% · USD 0.686 billion | Third-Line and Later 10.39% |
- Based on regional analysis, North America led the global elotuzumab market in 2025 with 51.97% of global revenue at USD 0.66 billion, reaching USD 1.264 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 15.04% in 2025 to 20% in 2034, with revenue growing from USD 0.191 billion to USD 0.538 billion.
- Middle East and Africa remains the smallest region throughout, at 2.52% of 2025 revenue and 3.01% by 2034.
- The fastest type line is 400mg Injection, forecast to compound at 9.36% through the period.
- The United States is the largest single country market at USD 0.607 billion in 2025, 47.8% of global revenue.
The study covers five axes, by type, and by application, distribution channel, combination regimen and treatment line, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 2.367 billion and USD 3.013 billion by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.